Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or …

…, M Ludwig, RE Felberbaum… - The Journal of …, 2003 - academic.oup.com
Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during
ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of …

Effect of luteinizing hormone–releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study

…, H Stehle, T Reimer, R Felberbaum… - Journal of clinical …, 2011 - ascopubs.org
Purpose Observational studies suggested that luteinizing hormone–releasing hormone agonists
(LHRHa) might prevent premature ovarian failure resulting from adjuvant chemotherapy …

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

…, G Feisel-Schwickardi, R Felberbaum… - The Lancet …, 2020 - thelancet.com
Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

RE Felberbaum, T Reissmann, W Küpker… - European Journal of …, 1995 - Elsevier
Objective: To examine the pituitary response in patients undergoing short-term application
of the GnRH antagonist Cetrorelix in the mid-cycle phase for hypophysial suppression of …

Breastfeeding duration is determined by only a few factors

E Peters, KH Wehkamp, RE Felberbaum… - … European Journal of …, 2006 - academic.oup.com
Background: According to a representative German study prepared between 1996 and 1998
(SuSe-Study) 90% of the mothers were willing to breastfeed, but only 33% (10%) of the …

GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry

G Griesinger, R Felberbaum, K Diedrich - Human Reproduction, 2005 - academic.oup.com
The place of GnRH antagonists in ovarian stimulation is controversial. Meta-analyses on
studies comparing GnRH agonist and GnRH antagonist treatment regimens have suggested a …

[HTML][HTML] Comparison of in vitro-and chorioallantoic membrane (CAM)-culture systems for cryopreserved medulla-contained human ovarian tissue

…, G Rahimi, F Nawroth, K Hancke, R Felberbaum… - PLoS …, 2012 - journals.plos.org
At present, there are three ways to determine effectively the quality of the cryopreservation
procedure using ovarian tissue before the re-implantation treatment: evaluation of follicles …

[HTML][HTML] Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients …

…, C Brucker, H Stauder, I Gröll, R Felberbaum… - Annals of …, 2023 - Elsevier
Background The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178)
evaluated the impact of CANKADO-based electronic patient-reported …

[HTML][HTML] Impact of reproductive history on in vitro fertilization and intracytoplasmic sperm injection outcome: evidence from the German IVF Registry

MS Kupka, C Dorn, O Richter, R Felberbaum… - Fertility and sterility, 2003 - Elsevier
OBJECTIVE: To evaluate the effect of reproductive history on the outcome of different
procedures in assisted reproductive technologies (ART) comparing IVF, ICSI, and cryopreserved …

[HTML][HTML] Physical activity in high-risk pregnancies

C Sitzberger, J Hansl, R Felberbaum… - Journal of Clinical …, 2022 - mdpi.com
It is known that physical activity before and during pregnancy is associated with health benefits
for both the mother and fetus. The WHO recommends a minimum of 150 min per week of …